Non-tuberculous mycobacteria in cystic fibrosis.
Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge,  UK.
Uta G
UG
Hill
R Andres
RA
Floto
Charles S
CS
Haworth
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015897:Comorbidity; D003550:Cystic Fibrosis / Q000453:epidemiology* / Q000382:microbiology* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D009170:Nontuberculous Mycobacteria / Q000302:isolation & purification*; D011379:Prognosis; D012129:Respiratory Function Tests; D012293:Rifampin; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D018942:Macrolides; D004977:Ethambutol; D012293:Rifampin